• AgraFlora (AGRA) received a newly issued Standard Processing License from Health Canada for edibles manufacturing facility in Winnipeg, Manitoba
  • The 51,000 square-foot fully automated facility employs state-of-the-art manufacturing equipment to produce pharmaceutical-grade quality cannabis edibles
  • With the licence in hand, AgraFlora is continuing to focus on devloping long-term production relationships
  • AgraFlora closed at C$0.03 per share

AgraFlora (AGRA) received a newly issued Standard Processing License from Health Canada for edibles manufacturing facility in Winnipeg, Manitoba.

AgraFlora Organics is focused primarily on the Canadian cannabis industry. It’s subsidiary, Edibles and Infusions Corporation will be located in the Winnipeg facility.

The 51,000 square-foot fully automated facility employs state-of-the-art manufacturing equipment to produce pharmaceutical-grade quality cannabis edibles with a precise level of consistency for improved dosing accuracy, consistent consumer experiences and increased consumer safety. 

Edibles and Infusions Corporation Co-Founder and Operational Founder James Fletcher said the company’s strong evidence package submission is a testament to the hard-working team it has assembled.

“We are now able to commercialize our formulations and bring to market cannabis activated pectin and gelatin gummies, hard candy, and sugar-free variants.”

Looking forward, AgraFlora intends to continue focusing on completing long-term production relationships through the culmination of the research and development trials through the company’s Health Canada license.

AgraFlora closed at C$0.03 per share.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.